VEGFA and non-small cell lung carcinoma: In NSCLC patients, RASi improved survival in carboplatin/paclitaxel-treated patients, but not when bevacizumab (anti-VEGF) was included, suggesting overlapping anti-angiogenic effects of bevacizumab and RASi [100].